ISSN: 2008-2258
Vol 13, (2020): Supplement1- Winter
Proteomic study of advanced cirrhosis based on HCV to reveal potential biomarkers
Gastroenterology and Hepatology from Bed to Bench,
,
,
Page S113-S121
https://doi.org/10.22037/ghfbb.v13i1.2219
Abstract
Aim: We aimed to carry out proteomic assessment of long-term effects of hepatitis C on liver.
Background: Cirrhosis is a condition where liver is damaged and loses its efficiency, and has the high rate of mortality in the world. Proteome profiling may help to identify important proteins and find the pathogenesis Cirrhosis is a condition where liver is damaged and loses its efficiency, and has the high rate of mortality in the world. Proteome profiling may help to identify important proteins and find the pathogenesis.
Methods: Here, by the application of two-dimensional polyacrylamide gel electrophoresis (2-D PAGE), combined with (MALDI-TOF-TOF MS), proteome profile of decompensated HCV cirrhosis is determined compared to healthy matched controls. Furthermore, Cytoscape has used network analysis. The proteome comparison between two groups identified proteins with significant expression changes (p<0.05 and fold change ≥ 1.5).
Results: We found upregulation of IGHA1, C3, A1BG, IGKC and one isoform of HP. Also, lower expression of APOA4 and the other spot of HP in advanced cirrhosis patients were revealed based on HCV compared to matched controls. According to network analysis, ALB has been introduced as a key protein, which may play an important role in pathogenesis.
Conclusion: Integration of the proteomics with protein interaction data led to the identification of several novel key proteins related to the immune system that may reflect the long-term effects of hepatitis C virus on the liver, and can introduce as therapeutic targets for advanced HCV- cirrhosis.
Keywords: Proteomic, liver cirrhosis, hepatitis C, Two-dimensional gel electrophoresis (2DE), Protein –protein interaction.
(Please cite as: Safaei A, Arefi Oskouie A, Mohebbi SR, Razaghi Z, Nejadi N. Proteomic study of advanced cirrhosis based on HCV to reveal potential biomarkers. Gastroenterol Hepatol Bed Bench 2020;13(Suppl.1):S113-S121).
- Proteomic, liver cirrhosis, hepatitis C, Two-dimensional gel electrophoresis (2DE), Protein –protein interaction
How to Cite
References
Zali MR, Mayumi M, Raoufi M, Nowroozi A. Hepatitis C virus genotypes in the Islamic Republic of Iran: a preliminary study. East Mediterr Health J. 2000;6:372-7.
Friedman SL. Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol Rev 2008;88:125-72.
Schuppan D, Afdhal NH. Liver cirrhosis. Lancet 2008;371:838-51.
Hussain SM, Semelka RC, Mitchell DG. MR imaging of hepatocellular carcinoma. Magn Reson Imag Clin N Am 2002;10:31-52.
Majumdar A, Kitson MT, Roberts SK. Treatment of Hepatitis C in Patients with Cirrhosis: Remaining Challenges for Direct-Acting Antiviral Therapy. Drugs 2015;75:823-34.
Mukerji AN, Patel V, Jain A. Improving survival in decompensated cirrhosis. Int J Hepatol 2012;74:214-34.
Fukumitsu K, Yagi H, Soto-Gutierrez A, editors. Bioengineering in organ transplantation: targeting the liver. Transplant Proc 2011;43:2137-8.
.8. Runyon BA, editor Historical aspects of treatment of patients with cirrhosis and ascites. Semin Liver Dis 1997;17:249-60.
Chandramouli K, Qian P-Y. Proteomics: challenges, techniques and possibilities to overcome biological sample complexity. Hum Genom Proteom 2009;2009:1-22.
Kalantari S, Rutishauser D, Samavat S, Nafar M, Mahmudieh L, Rezaei-Tavirani M, et al. Urinary prognostic biomarkers and classification of IgA nephropathy by high resolution mass spectrometry coupled with liquid chromatography. PLoS One 2013;8:530-45.
Zali H, Ahmadi G, Bakhshandeh R, Rezaei-Tavirani M. Proteomic analysis of gene expression during human esophagus cancer. J Paramed Sci 2011;2:210-23.
Rezaie-Tavirani M, Fayazfar S, Heydari-Keshel S, Rezaee MB, Zamanian-Azodi M, Rezaei-Tavirani M, et al. Effect of essential oil of Rosa Damascena on human colon cancer cell line SW742. Gastroenterol Hepatol Bed Bench 2013;6:25-31.
Zamanian-Azodi M, Rezaie-Tavirani M, Heydari-Kashal S, Kalantari S, Dailian S, Zali H. Proteomics analysis of MKN45 cell line before and after treatment with Lavender aqueous extract. Gastroenterol Hepatol Bed Bench 2011;5:76-87.
Rezaei-Tavirani M, Rahmati-Rad S, Rezaei-Tavirani M. Ethanol and Cancer Induce Similar Changes on Protein Expression Pattern of Human Fibroblast Cell. Iran J Pharm Sci 2016;15:175-84.
Hasanzadeh H, Rezaie-Tavirani M, Seyyedi S, Emadi A. Proteomics Study of extremely low frequency electromagnetic field (50 Hz) on human neuroblastoma cells. Koomesh 2015;17:233-8.
Craven RA, Stanley AJ, Hanrahan S, Dods J, Unwin R, Totty N, et al. Proteomic analysis of primary cell lines identifies protein changes present in renal cell carcinoma. Proteomics 2006;6:2853-64.
Uto H, Kanmura S, Takami Y, Tsubouchi H. Clinical proteomics for liver disease: a promising approach for discovery of novel biomarkers. Proteome Sci 2010;8:1-19.
orbin IR, Ryner LN, Singh H, Minuk GY. Quantitative hepatic phosphorus-31 magnetic resonance spectroscopy in compensated and decompensated cirrhosis. Am J Physiol Gastrointest Liver Physiol 2004;287:G379-84.
Ahmad J, Downey KK, Akoad M, Cacciarelli TV. Impact of the MELD score on waiting time and disease severity in liver transplantation in United States veterans. Liver Transpl 2007;13:1564-9.
Yu H, Kim PM, Sprecher E, Trifonov V, Gerstein M. The importance of bottlenecks in protein networks: correlation with gene essentiality and expression dynamics. PLoS Comput Biol 2007;3: 59-61.
Bindea G, Mlecnik B, Hackl H, Charoentong P, Tosolini M, Kirilovsky A, et al. ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks. Bioinformatics 2009;25:1091-3.
Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res 2003;13:2498-504.
Malekzadeh R, Mohamadnejad M, Rakhshani N, Nasseri-Moghaddam S, Merat S, Tavangar SM, et al. Reversibility of cirrhosis in chronic hepatitis B. Clin Gastroenterol Hepatol 2004;2:344-7.
Rossi E, Adams LA, Bulsara M, Jeffrey GP. Assessing liver fibrosis with serum marker models. Clin Biochem Rev 2007;28:3-12.
Xue R, Dong L, Wu H, Liu T, Wang J, Shen X. Gas chromatography/mass spectrometry screening of serum metabolomic biomarkers in hepatitis B virus infected cirrhosis patients. Clin Chem Lab Med 2009;47:305-10.
Montaser-Kouhsari L. Plasma myeloperoxidase activity and apolipoprotein A-1 expression in chronic hepatitis B patients. Arch Iran Med 2011;14:254-63.
Körmöczi G, Säemann M, Buchta C, Peck‐Radosavljevic M, Mayr W, Schwartz D, et al. Influence of clinical factors on the haemolysis marker haptoglobin. Eur J Clin Invest 2006;36:202-9.
Cooksley W, Powell L, Halliday J. Reticuloendothelial phagocytic function in human liver disease and its relationship to haemolysis. Br J Haematol 1973;25:147-64.
Hiramatsu S, Kojima J, Okada T, Inai S, Ohmori K. The serum protein profile in chronic hepatitis, cirrhosis and liver cancer. Acta Hepatogastroenterol 1976;23:177-82.
Mondal G, Saroha A, Bose PP, Chatterjee B. Altered glycosylation, expression of serum haptoglobin and alpha-1-antitrypsin in chronic hepatitis C, hepatitis C induced liver cirrhosis and hepatocellular carcinoma patients. Glycoconj J 2016;33:209-18.
Gangadharan B, Bapat M, Rossa J, Antrobus R, Chittenden D, Kampa B, et al. Discovery of novel biomarker candidates for liver fibrosis in hepatitis C patients: a preliminary study. PLoS One 2012;7:271-83:
Rossi E, Adams L, Prins A, Bulsara M, de Boer B, Garas G, et al. Validation of the FibroTest biochemical markers score in assessing liver fibrosis in hepatitis C patients. Clin Chem 2003;49:40-9.
Zhang Z, Bast RC, Yu Y, Li J, Sokoll LJ, Rai AJ, et al. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res 2004;64:5882-90.
Chrostek L, Supronowicz L, Panasiuk A, Cylwik B, Gruszewska E, Flisiak R. The effect of the severity of liver cirrhosis on the level of lipids and lipoproteins. Int J Clin Exp Med 2014;14:417-21.
Pollo-Flores P, Cásseres D, Zampier L, Adnet G, Shiroma M, Padua L, et al. Lipid Metabolism and Interleukin 28B Polymorphism in Hepatitis C. J Infec Dis Treat 2016;2:1-12.
Ellison III RT, Horsburgh Jr CR, Curd J. Complement levels in patients with hepatic dysfunction. Dig Dis Sci 1990;35:231–35.
Homann C, Varming K, Høgåsen K, Mollnes T, Graudal N, Thomsen AC, et al. Acquired C3 deficiency in patients with alcoholic cirrhosis predisposes to infection and increased mortality. Gut 1997;40:544-9.
Baumann M, Witzke O, Canbay A, Patschan S, Treichel U, Gerken G, et al. Serum C3 complement concentrations correlate with liver function in patients with liver cirrhosis. Hepatogastroenterology 2003;51:1451-3.
Mas VR, Fassnacht R, Archer KJ, Maluf D. Molecular mechanisms involved in the interaction effects of alcohol and hepatitis C virus in liver cirrhosis. Mol Med 2010;16:287-97.
Dillon ST, Bhasin MK, Feng X, Koh DW, Daoud SS. Quantitative proteomic analysis in HCV-induced HCC reveals sets of proteins with potential significance for racial disparity. J Transl Med 2013;11:239-50.
Bernardi M, Maggioli C, Zaccherini G. Human albumin in the management of complications of liver cirrhosis. Crit Care 2012;16:211-20.
Hueging K, Weller R, Doepke M, Vieyres G, Todt D, Wölk B, et al. Several human liver cell expressed apolipoproteins complement HCV virus production with varying efficacy conferring differential specific infectivity to released viruses. PLoS One 2015;10:314-21.
White IR, Patel K, Symonds WT, Dev A, Griffin P, Tsokanas N, et al. Serum proteomic analysis focused on fibrosis in patients with hepatitis C virus infection. J Transl Med 2007;5:33-40.
Goudarzi M, Goudarzi H, Alebouyeh M, Azimi Rad M, Shayegan Mehr FS, Zali MR, et al. Antimicrobial susceptibility of clostridium difficile clinical isolates in iran. Iran Red Crescent Med J 2013;15:704-11.
Safaei A, Tavirani MR, Oskouei AA, Azodi MZ, Mohebbi SR, Nikzamir AR. Protein-protein interaction network analysis of cirrhosis liver disease. Gastroenterol Hepatol Bed Bench 2016;9:114-21.
Gray J, Chattopadhyay D, Beale GS, Patman GL, Miele L, King BP, et al. A proteomic strategy to identify novel serum biomarkers for liver cirrhosis and hepatocellular cancer in individuals with fatty liver disease. BMC Cancer 2009;9:271-82.
Martínez-Esparza M, Tristán-Manzano M, Ruiz-Alcaraz AJ, García-Peñarrubia P. Inflammatory status in human hepatic cirrhosis. World J Gastroenterol 2015;21:145-56.
Lindgren S, Laurell AB, Eriksson S. Complement components and activation in primary biliary cirrhosis. Hepatol 1984;4:9-14.
Tietge U, Boker K, Bahr M, Weinberg S, Pichlmayr R, Schmidt H, et al. Lipid parameters predicting liver function in patients with cirrhosis and after liver transplantation. Hepatogastroenterology 1997;45:2255-60.
- Abstract Viewed: 0 times
- PDF Downloaded: 0 times
